Sasanlimab  (Synonyms: PF-06801591)

Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

PDCD1/PD-1/CD279

Sasanlimab binds with high affinity to human and cynomolgus monkey PD-1, and shows no detectable binding to rat PD-1^[2].
Sasanlimab (1 h) binds with high affinity to cell surface-expressed human and cynomolgus monkey PD-1 (EC₅₀ values 51.04-222.55 pM across primary and transfected T cell models), shows minimal binding to mouse PD-1, and no detectable binding to rat PD-1^[2].
Sasanlimab (serial dilutions, pmol/L range; 1 h) potently blocks the interaction of cell surface-expressed human and cynomolgus monkey PD-1 with their ligands PD-L1 and PD-L2, with IC₅₀ values ranging from 839-1,058 pM^[2].
Sasanlimab reverses PD-1/PD-L1-mediated inhibition of NFAT signaling in human PD-1-expressing Jurkat T cells, with an IC₅₀ of 0.33 μg/mL^[2].
Sasanlimab (10^-5-10¹ μg/mL; 5 days) dose-dependently enhances human T-cell proliferation and production of IFNγ, TNFα, and IL2 in mixed lymphocyte reaction assays with PD-L1-expressing cells^[2].
Sasanlimab (0.01-100 μg/mL; 1 h) dose-dependently enhances SEB-induced production of IFNγ, TNFα, and IL2 in cynomolgus monkey whole blood^[2].
Sasanlimab does not mediate significant antibody-dependent cell-mediated cytotoxicity against activated human T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sasanlimab (0.1-10 mg/kg; 2 doses at 2 and 8 days after PBMC transfer) accelerates acute xenogeneic GvHD in NSG mice in a dose-dependent manner^[2].
Sasanlimab (10 mg/kg; intraperitoneal injection; 4 doses at days 10, 13, 16, and 23 after tumor inoculation) substantially delays the growth of established MC-38 colon adenocarcinoma tumors in human PD-1 knock-in mice without inducing toxicity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.438 kDa

2206792-50-7

Liquid

Colorless to light yellow

[Sasanlimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometric analysis of 500 ng/mL Ionomycin (HY-13434) and 20 ng/mL PMA (HY-18739) co-stimulated 1X10⁶ Jurkat cells (4h) with Sasanlimab ( red). Cells stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluo 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.

• [1]. Shore ND, et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025;31(8):2806-2814.

  [2]. Al-Khami AA, et al. Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020;19(10):2105-2116.